Page 65 - congress

ORAL PRESENTATION / TAM METİN SÖZLÜ SUNUM

European Medicines Agency, EMA (2018). Guideline on the reporting of physiologically based
pharmacokinetic (PBPK) modelling and simulation. In: European Medicines Agency London,
UK.
Foti RS. (2024). Utility of physiologically based pharmacokinetic modeling in predicting and
characterizing clinical drug interactions. Drug Metabolism and Disposition, 100021.
Gaohua L, Neuhoff S, Johnson TN, Rostami-Hodjegan A, Jamei M. (2016). Development of a
permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate
known physiological and biological knowledge: Estimating time varying CSF drug
concentrations and their variability using in vitro data. Drug metabolism and pharmacokinetics,
31(3), 224-233.
Gastroplus (2025). Erişim tarihi: 28.05.2025 05:42. Erişim adresi: https://www.simulations-
plus.com/software/gastroplus/.
Gong Y, Korzekwa K, Nagar S. (2025). Rat PermQ: A permeability-and perfusion-based physiologically
based pharmacokinetic model for improved prediction of drug concentration-time profiles in
rat. Drug Metabolism and Disposition, 53(2).
Goodman LS. (1996). Goodman and Gilman's the pharmacological basis of therapeutics (Vol. 1549).
McGraw-Hill New York.
Hartmanshenn C, Scherholz M, Androulakis IP. (2016). Physiologically-based pharmacokinetic
models: approaches for enabling personalized medicine. Journal of pharmacokinetics and
pharmacodynamics, 43, 481-504.
Hedaya MA. (2023). Basic pharmacokinetics. Routledge.
Henriot J, Dallmann A, Dupuis F, Perrier J, Frechen S. (2025). PBPK modeling: What is the role of
CYP3A4 expression in the gastrointestinal tract to accurately predict first‐pass metabolism?
CPT: pharmacometrics & systems pharmacology, 14(1), 130-141.
Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. (2009). The Simcyp®
population-based ADME simulator. Expert opinion on drug metabolism & toxicology, 5(2), 211-
223.
Jones H, Chen Y, Gibson C, Heimbach T, Parrott N, Peters S, Snoeys J, Upreti V, Zheng M, Hall S.
(2015). Physiologically based pharmacokinetic modeling in drug discovery and development:
a pharmaceutical industry perspective. Clinical Pharmacology & Therapeutics, 97(3), 247-262.
Khalil F, Läer S. (2011). Physiologically based pharmacokinetic modeling: methodology,
applications, and limitations with a focus on its role in pediatric drug development. BioMed
Research International, 2011(1), 907461.
Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D.
(2016). Applied concepts in PBPK modeling: how to build a PBPK/PD model. CPT:
pharmacometrics & systems pharmacology, 5(10), 516-531.
Lautz L, Dorne J, Oldenkamp R, Hendriks A, Ragas A. (2020). Generic physiologically based kinetic
modelling for farm animals: Part I. Data collection of physiological parameters in swine, cattle
and sheep. Toxicology Letters, 319, 95-101.
Lautz L, Hoeks S, Oldenkamp R, Hendriks A, Dorne J, Ragas A. (2020). Generic physiologically based
kinetic modelling for farm animals: Part II. Predicting tissue concentrations of chemicals in
swine, cattle, and sheep. Toxicology Letters, 318, 50-56.
Lautz L, Oldenkamp R, Dorne J, Ragas A. (2019). Physiologically based kinetic models for farm
animals: Critical review of published models and future perspectives for their use in chemical
risk assessment. Toxicology in Vitro, 60, 61-70.

62